About us
The independent Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG) examines the benefits and harms of medical interventions for patients.
Projects
Participation
Events
Press
Contact
Breadcrumbs
Introduction
Prof. Dr. Ralf Bender (IQWiG)
HTA meets EMA – Methodological areas of debate from an industry point of view
Dr. Claudia Nicolay (Eli Lilly) & Friedhelm Leverkus (Pfizer)
The regulatory process between confirmatory studies and benefit-risk assessment
Dr. Jan Müller-Berghaus (Paul-Ehrlich-Institut, PEI)
Decision strategies in approval and benefit assessment from a biometric point of view
Prof. Dr. Armin Koch & Yvonne Ziert (Hannover Medical School)
How reliable are HTA decisions based on single RCTs?
Prof. Dr. Gerald Gartlehner (Danube University Krems, Austria)
Summary
PD Dr. Stefan Lange (IQWiG)
Programme
Abstracts of the presentations
